Nunamaker Elizabeth A, Stolarik DeAnne F, Ma Junli, Wilsey Amanda S, Jenkins Gary J, Medina Chris L
Biologic Resources Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA; Department of Comparative Medicine, Abbvie, North Chicago, Illinois, Animal Care Services, University of Florida, Gainesville, Florida, USA.
Drug Metabolism and Pharmacokinetics, Abbvie, North Chicago, Illinois, USA.
J Am Assoc Lab Anim Sci. 2014 Sep;53(5):494-501.
The goal of the current study was to compare the efficacy, adverse effects, and plasma buprenorphine concentrations of sustained-release buprenorphine (SRB) and buprenorphine after subcutaneous administration in dogs undergoing ovariohysterectomy. In a prospective, randomized, blinded design, 20 healthy adult female Beagle dogs underwent routine ovariohysterectomy and received multimodal analgesia consisting of meloxicam and one of two buprenorphine formulations. Dogs were randomly assigned to receive either SRB (0.2 mg/kg SC, once) or buprenorphine (0.02 mg/kg SC every 12 h for 3 d). Blinded observers assessed all dogs by using sedation scores, pain scores, temperature, HR, RR, and general wellbeing. Dogs were provided rescue analgesia with 0.02 mg/kg buprenorphine SC if the postoperative pain score exceeded a prede- termined threshold. Blood samples were collected, and mass spectrometry was used to determine plasma buprenorphine concentrations. Data were analyzed with a linear mixed model and Tukey-Kramer multiple comparison. Age, body weight, anesthetic duration, surgical duration, sevoflurane concentration, and cardiorespiratory variables did not differ significantly between groups. Dogs in both formulation groups had comparable postoperative sedation and pain scores. One dog from each formulation group had breakthrough pain requiring rescue analgesia. Plasma buprenorphine concentrations remained above a hypothesized therapeutic concentration of 0.6 ng/mL for 136.0 ± 11.3 and 10.67 ± 0.84 h for SRB and buprenorphine, respectively. Based on the results of this study, multimodal analgesic regimens consisting of meloxicam and either buprenorphine or SRB are equally efficacious in managing pain associated with an ovariohysterectomy and show comparable side effects.
本研究的目的是比较在接受卵巢子宫切除术的犬皮下注射缓释丁丙诺啡（SRB）和丁丙诺啡后的疗效、不良反应及血浆丁丙诺啡浓度。在一项前瞻性、随机、盲法设计中，20只健康成年雌性比格犬接受常规卵巢子宫切除术，并接受由美洛昔康和两种丁丙诺啡制剂之一组成的多模式镇痛。犬被随机分配接受SRB（0.2mg/kg皮下注射，一次）或丁丙诺啡（0.02mg/kg皮下注射，每12小时一次，共3天）。盲法观察者通过使用镇静评分、疼痛评分、体温、心率、呼吸频率和总体健康状况对所有犬进行评估。如果术后疼痛评分超过预定阈值，则给犬皮下注射0.02mg/kg丁丙诺啡进行解救镇痛。采集血样，并用质谱法测定血浆丁丙诺啡浓度。数据采用线性混合模型和Tukey-Kramer多重比较进行分析。两组之间的年龄、体重、麻醉持续时间、手术持续时间、七氟醚浓度和心肺变量无显著差异。两个制剂组的犬术后镇静和疼痛评分相当。每个制剂组有一只犬出现突破性疼痛，需要解救镇痛。SRB和丁丙诺啡的血浆丁丙诺啡浓度分别在136.0±11.3小时和10.67±0.84小时内保持在假设的治疗浓度0.6ng/mL以上。基于本研究结果，由美洛昔康和丁丙诺啡或SRB组成的多模式镇痛方案在管理与卵巢子宫切除术相关的疼痛方面同样有效，且副作用相当。
